Metabolomic studies conducted for evaluating cancer pathogenesis and progression by monitoring the amino acids metabolic balance hold great promise for assessing current and future anticancer treatments. We performed a comprehensive quantification of 21 amino acids concentrations in cultured human colorectal adenocarcinoma cells treated with the anticancer drugs 5-fluorouracil, irinotecan, and cisplatin. A precolumn fluorescence derivatization-HPLC method involving 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate was used. Amino acid concentration data were analyzed by principal-component analysis and partial least-squares multivariate statistical methods to represent samples on two-dimensional graphs. The hierarchical cluster analysis and linear discriminant analysis were used to classify the samples on the score plots. Unlike the cluster analysis approach, the linear discrimination analysis classification successfully distinguished anticancer drug-treated samples from the untreated controls. Moreover, three candidate amino acids (serine, aspartic acid, and methionine) were identified from the loading plots as potential biomarkers. Our proposed method might be able to evaluate the effectiveness of anticancer therapy even in small laboratories or medical institutions.
Introduction
Chemotherapy using anticancer drugs forms the mainstay of current cancer treatments. However, the narrow therapeutic range of these pharmaceutical agents makes it extremely difficult to selectively eradicate cancer cells without eliciting the side effects of chemotherapy. Differences in the drug response between individuals make successful treatment even more difficult to attain. To achieve effective cancer treatment, an anticancer drug sensitivity test is currently performed at many medical institutions. This test uses in vitro tumor tissue collected during surgery, or by endoscopy, to determine the therapeutic effectiveness of anticancer drugs by evaluating the survival of the cancer cells. Because this method assess the effectiveness of the drugs by only the life-or-death condition of the cancer cells, it was difficult to trace any process concerning the death of cancer cells. Additionally, this method suffers from a high true-negative rate and low true-positive rate. 1 The development of a more precise predictive method that would enable the optimization of dosage to the individual and predict the patient's drug sensitivity has been the goal of cancer treatment research for the past decades.
An imbalance in amino acid metabolism is believed to play a role in the pathogenesis of a number of diseases, including cancer, 2 liver failure, 3, 4 renal failure, 5 diabetes, 6 and amino acid concentration anomalies such as phenylketonuria. 7 Recently, Zhang et al. have reported a new statistical approach-a socalled "amino-index"-that uses the plasma amino acid profile for the diagnosis of hepatic fibrosis. 3, 4 The uptake of amino acids into cancer cells is thought to be enhanced in comparison to that in normal cells. 8 Our goal was to develop a method that determines the therapeutic efficacy of anticancer drugs based on the changes in amino acid metabolism at the cellular level. In this study, we evaluated the effects of various anticancer drugs on cell growth by amino acid metabolomics assessment of the cell culture medium. A schematic diagram depicting the principles of the amino acid metabolomics approach is presented in Fig. 1 . We measured the concentrations of amino acids in the medium of cultured human colorectal adenocarcinoma cells (Colo201) treated with three chemotherapeutic agents with distinct mechanisms of anticancer action.
5-Fluorouracil (5-FU) is a thymidylate synthase inhibitor, irinotecan (CPT-11) is a topoisomerase I inhibitor, and cisplatin (CDDP) is a DNA cross-linker. Successful execution of a comprehensive metabolomic analysis requires precise, sensitive, and robust methods of amino acid detection and measurement.
A number of techniques for measuring amino acid levels have been reported. [9] [10] [11] [12] [13] Although most of these approaches rely on liquid chromatography mass spectrometry (LC-MS) instruments for metabolomics studies, their use is limited to the relatively large institutions because the equipment is still large and expensive. Conversely, high-performance liquid chromatography (HPLC) systems are relatively small and common in medical and research laboratories. HPLC analysis following precolumn fluorescence derivatization allows the detection of amino acids at femtomole-level concentrations in biological samples, and is gaining recognition as a powerful tool with high sensitivity and selectivity.
Fluorescence derivatization reagents, such as o-phthalaldehyde, 14,15 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC), [16] [17] [18] fluorescein isothiocyanate, 19, 20 dansyl chloride, 21, 22 and 4-fluoro-7-nitrobenzofurazan, 23, 24 are commercially available for the metabolomic analysis of amino acids. For a comprehensive analysis of amino acids, high sensitivity of the detection system and good chemical stability of derivatives are required. We thus selected the AccQ Tag method 25 using AQC as a fluorogenic precolumn derivatization reagent. It satisfies these criteria, and exhibits the optimal profile for metabolomic applications, since it has high sensitivity, good reproducibility, and long-term stability of its fluorescent derivatives (at least 1 week at room temperature). 26, 27 Furthermore, we aim to use principal component analysis (PCA) and partial least-squares (PLS) multivariate statistical analyses with linear discriminant analysis (DA) and hierarchical cluster analysis (CA) of score plots to analyze the quantitative data obtained using this technique.
Experimental

Reagents and chemicals
Ultrapure water was produced by a Milli-Q Plus system (Merck Millipore, Billerica, MA). RPMI 1640 medium, fetal calf serum (FCS), and nonessential amino acids were purchased from GIBCO (Auckland, New Zealand). AccQ Tag Reagent Kit was purchased from Waters (Milford, MA). The kit consists of AccQ Fluor borate buffer, AccQ Fluor reagent powder (AQC), AccQ Fluor reagent diluent, and amino acid hydrolysate standard (a mixture of 16 hydrolysate amino acids: Asp, Ser, Glu, Gly, His, Arg, Thr, Ala, Pro, Tyr, Val, Met, Lys, Ile, Leu, and Phe at a concentration of 2.5 and 1.25 mM L-cystine (Cyss)). 5-Fluorouracil (5-FU), irinotecan hydrochloride (CPT-11), cis-diammineplatinum(II) dichloride (CDDP), sodium pyruvate, and α-aminobutyric acid (ABA) were purchased from Sigma Aldrich (St. Louis, MO). Asn monohydrate, Gln, and HPLC-grade acetonitrile were purchased from Kanto Chemical (Tokyo, Japan). L-Hydroxyproline (HyPro), sodium acetate trihydrate, and phosphoric acid were purchased from Wako Pure Chemical (Osaka, Japan). Trp and L-ornithine (Orn) were obtained from Kishida Chemical (Osaka, Japan) and Kyowa Hakko Kirin (Tokyo, Japan), respectively.
Stock solutions of Asn, Gln, HyPro, Orn (250 mM), and Trp (100 mM) were prepared by dissolving the amino acids in a Fig. 1 Schematic diagram depicting the procedures involved in the amino acid metabolomics study evaluating the effect of anticancer drugs used in cell cultures by using multivariate analyses (PCA and PLS) and data classification (cluster and discriminant analyses). 0.1 M hydrochloric acid solution. A stock solution (10 mM) of ABA was prepared in 0.1 M hydrochloric acid, and was further diluted to 0.4 mM before use. A standard mixture solution of 22 amino acids (2.27 mM concentration, except for Cyss at 1.14 mM), were prepared by mixing a solution containing 17 standards and a solution of 5 amino acids, and then diluting the resulting combined mixture with 0.1 M hydrochloric acid. Solutions of 5-FU, CPT-11, and CDDP were prepared in dimethylsulfoxide and further diluted to the required concentrations with physiological saline just before use.
Cultured cells
Human colon adenocarcinoma cells Colo201 were obtained from American Type Culture Collection (Manassas, VA). RPMI 1640 medium containing 10% FCS, nonessential amino acids, and sodium pyruvate was used. Colo201 cells were cultured in a humidified incubator with 5% CO2 at 37 C. The cells were sub-cultured when they were observed to be 80% confluent in the flask.
Determination of anticancer drugs IC50 in Colo201 cells
Measurements of cell viability by the WST-1 assay were used to calculate the IC50 values of each anticancer drug in Colo201 cells. 28 The WST-1 assay was performed in accordance with the manufacturer's instructions (Roche Diagnostics, Basel, Switzerland). Briefly, cells were seeded (1.25 × 10 4 cells/well) in 100 μL of a culture medium containing a range of concentrations from 0.1 to 50 μg mL -1 of 5-FU, CPT-11, or CDDP, and incubated for 72 h. The cells were incubated with 10 μL of a WST-1 reagent solution for the last 4 h. The absorbance of each sample was measured at 450 nm by using a Bio-Rad 550 Microplate Reader (Bio-Rad, Hercules, CA). Each assay was performed in triplicate.
Medium sample obtained following anticancer drug treatment
Seeded cells (5 × 10 4 cells/well) were incubated for 72 h in 1 mL of a culture medium containing each anticancer drug at concentrations near to the IC50 value determined using the methods described above. Cells cultured under identical conditions without the drug treatments were used as controls. At 0, 12, 24, 36, 48, and 72 h from the beginning of incubation, 100 μL of samples of the medium were collected from each well into 1.5-mL centrifuge tubes. Tubes were mixed by vortexing the following addition of 100 μL of a 0.4 mM ABA solution as the internal standard. After the addition of 200 μL of acetonitrile, the mixture was centrifuged at 16000g for 5 min at 4 C, and the resulting supernatant was subjected to the derivatization procedure.
Derivatization
The derivatization reaction for amino acids with the AQC reagent was performed according to the manufacturer's instructions. 27 Briefly, 10 μL of the standard solution or cell medium was mixed with 70 μL of an AccQ Fluor borate buffer. Following the addition of 20 μL of AccQ Fluor reagent solution, the combined solution was immediately mixed. After standing for 1 min at room temperature, the solution was heated at 55 C for 10 min. A 5-μL aliquot of the resulting solution was injected into the HPLC system.
HPLC-based amino acid quantification
An Alliance HPLC system (Waters) consisting of a 2695 Separation module and a 2475 Multi λ fluorescence detector was used. The fluorescence excitation and emission wavelengths of the detector were set at 250 and 395 nm, respectively. An AccQ Tag amino acid column (150 mm × 3.9 mm i.d., particle size 4 μm; Waters) was used, being kept at a constant column temperature of 39 C. For each separation, 5 μL of the derivatized sample was injected. The mobile phase used consisted of eluent A (AccQ Tag eluent A), B (AccQ Tag eluent B), C (acetonitrile), and D (water), with the flow rates and gradient profiles based on parameters presented by Wandelen et al. 16 Data acquisition was achieved via the Empower 2 software package (Waters) , with the height of the peaks used to calculate the concentrations of amino acids in comparison with the standard.
Statistical analysis
The amino acid concentrations in each medium sample were presented as the average of 5 repeated measurements. During this process, Smirnov-Grubbs' rejection test was performed using the following equation 29, 30 to identify outliers:
where, x* is the outlier value, μ the sample average, and σ the standard deviation of measured values. If the normalized variate was higher than 1.672, which is a critical value (n = 5, p-value = 0.05), the value was rejected.
Since the concentrations of ammonia and 21 amino acids in the culture medium were very different in the individual analyses, concentration data were normalized using the following equation:
where, x is the measured concentration, μ the average of concentrations measured from 0 to 72 h, and σ the standard deviation of the concentrations measured from 0 to 72 h. The calculated normalized values were exported to SIMCA-P+ software 12.0 (Umetrics, Umeå, Sweden) for multivariate statistical analyses, and three principal components were calculated (PC1, PC2, and PC3). Contribution ratios represented the contribution of a component to the total variance in the data. The DA and the CA analyses using Ward's minimum variance method were sequentially carried out using the SPSS15.0 Base system (SPSS Japan, Tokyo, Japan). Each sample was classified by the CA into several groups according to the dendrogram (tree diagram) obtained, and respective groups were circled on score plots. The discrimination rate was calculated using the following equation:
where, Ndet is the number of samples that were determined correctly and Ntotal the total number of samples. The statistical significance between the amino acid concentrations of each sample was analyzed using SPSS Statistics 19 software (SPSS Japan). First, the equality of the variances was examined using Levene's test. For the amino acid concentrations that did not show homogeneity, the non-parametric test of Kruskal-Wallis analysis was used to test for a significant difference between all groups. For the amino acid concentrations that showed homoscedasticity, the one-way analysis of variance (ANOVA) was used. If a significant difference was detected, Dunett's post hoc test was used for multiple comparisons between each anticancer drug treatment group and the control group. In all analyses, a p-value of less than 0.05 was considered to be statistically significant.
Results and Discussion
Determination of amino acids in cell culture samples Figure 2 shows a representative chromatogram depicting peaks corresponding to the 21 amino acids, the internal standard (ABA), and ammonia obtained from a sample of Colo201 cell culture medium following incubation for 12 h. Each of the amino acids and ammonia were detected using the fluorescence approach as a respective single peak within 45 min of injection into the HPLC system, without any notable interference from matrix components in the medium.
The precision of the quantitative determination was confirmed by calculating the relative standard deviations (RSDs) of the amino acid concentrations measured in a single well, which were determined to be 7.6% or less (Tables S1 -S3, Supporting Information). These results suggested that a single analysis per well is sufficient for quantitative determination when multiple replicates should be performed in parallel at each time point to provide adequate evidence.
Determination of IC50 values of each anticancer drug for Colo201 cells
The IC50 values of the anticancer drugs were determined to be 13 μg mL -1 (5-FU), 19 μg mL -1 (CPT-11), and 15 μg mL -1 (CDDP), by using the WST-1 test in Colo201 cells. Based on these IC50 values, the following concentrations of anticancer drugs were used in subsequent metabolomics studies: 10 μg mL -1 5-FU, 20 μg mL -1 CPT-11, and 20 μg mL -1 CDDP. For the CDDP treatment, a concentration of 20 μg mL -1 was used, which was higher than the IC50 value. From the doseresponse curve, the viability of Colo201 cells at CDDP concentrations of 20 μg mL -1 was estimated to be approximately 20%.
PCA analyses of cell culture medium following treatment with anticancer drugs
Data on normalized amino acid concentrations (presented in Supporting Information) were exported to SIMCA-P+ software for PCA analyses. Twenty-one variables were accounted equally in the datasets. Figure 3 (upper lane) and the DA (lower lane) approach. Using the PCA score plot, any differences in the amino acids composition of each sample were visually represented in the coordinates on the two-dimensional graphs.
The contribution ratios of the components and the discrimination rates obtained by PCA analyses are summarized in Table 1 .
In a score plot representing the data following treatment with 5-FU (Fig. 3a) , PC1 and PC3 scores accounted for 69.3% of the total variability detected. Although the CA approach could not fully differentiate between the two groups, the DA approach successfully discriminated between samples derived from 5-FUtreated and untreated cells.
In evaluating the data obtained following a treatment with CPT-11, the combined contribution of PC1 and PC2 was 84.3%. Although this value fully explained the overall detected trend, CPT-11-treated and untreated groups could not be distinguished by either the CA or DA classification approach. The combined contribution ratios of PC2 and PC3 (Fig. 3b) accounted for 36.8% of the total variability. In this plot, the DA approach discriminated between the CPT-11-treated and the untreated groups.
Finally, data obtained following treatments with CDDP demonstrated that PC1 and PC2 contribution ratios accounted for 91.2% of the variance in the data. Although this value fully explained the overall trend, samples obtained from CDDPtreated and untreated cells could not be discriminated by either the CA or the DA approach. In a plot depicting PC1 and PC3 (Fig. 3c) with the sum of the two scores accounting for 66.5% of the total detected variability, the DA approach successfully discriminated between CDDP-treated and untreated groups. Since the amino acid concentrations measured in the CDDPtreated sample at 0 h were almost identical to the concentrations in the control sample at same point, it is not surprising that the CDDP-treated sample at 0 h was classified as an untreated sample.
However, the 5-FU-treated sample at 0 h was distinguished from the control sample at 0 h. Although the cause of this difference was unknown, it might result from the time lag in the sample preparation.
PLS analyses of anticancer drug treated cell culture
Since the PCA expresses data obtained while maximizing their distribution, it can be utilized for analyzing the differences between individual samples. On the other hand, the PLS approach emphasizes the classification of the samples, and is therefore better suited for categorizing the samples. Table 2 .
In a score plot depicting data following treatments with 5-FU, PC1 and PC2, the contribution ratios combined accounted for 81.3% of the total variability (Fig. 4a) . Although the CA approach could not distinguish between the 5-FU-treated and untreated groups, the DA approach successfully discriminated between the two groups. The sum of the contribution ratios of PC1 and PC2 was at 78.9% in samples obtained following the CPT-11 treatment. Although this value fully explained the variance in the data, treated and untreated samples could not be discriminated by either of the two classifying techniques used. Conversely, the PC1 and PC3 scores combined explained 59.5% of the total variability, and a DA analysis of the two contributing ratios discriminated correctly between CPT-11-treated and untreated samples.
In a score plot representing data obtained from samples treated with CDDP, PC1 and PC2, the contribution ratios combined were 78.9%. Although samples treated with CDDP and untreated control samples could be distinguished by the DA approach, plotting PC1 and PC3 provided even better discrimination between the groups (Fig. 4c) . The contribution ratios PC1 and PC3 together explained 62.7% of the total variability. By using the CA approach, samples treated with CDDP and untreated samples were successfully separated into two distinct clusters, except for the control (untreated) sample obtained at 72 h. Additionally, the DA approach could discriminate between the two groups.
Use of loading plots of PCA and PLS analyses to identify marker candidates
PCA and PLS loading plots from each of the analyses depicted in Figs. 3 and 4 are presented in Fig. 5 . Several amino acids that significantly contributed to the distinguishing differences between the samples treated with anticancer drugs groups and untreated controls were identified.
In the 5-FU treatment, the results of both PCA-DA and PLS-DA analyses suggested that Ser and Asp contribute to the differences between the anticancer drug-treated group and the control samples. Similarly, both analyses suggested that Lys and Met contributed significantly to the differences observed between the groups in the CPT-11 and CDDP-treatments, respectively. The amino acids identified from the loading plots were different for each drug-treatment groups. Importantly, these amino acids may be of interest as candidate markers, since the results obtained following the 5-FU and CDDP-treatments support the findings of previous studies. [31] [32] [33] However, further research is warranted to confirm the selection of amino acids and to evaluate their relationships with different anticancer mechanisms of action.
The changes in the concentration of each amino acid in the Colo201 cell culture medium samples following treatments with (a) 5-FU, (b) CPT-11, (c) CDDP, and (d) control are summarized in Fig. 6 , as compared to the concentrations measured at the start of incubation. Marked changes in the concentrations of His, Ala, and Orn were observed following cell incubation in all analyses. Furthermore, the degree of change in the concentrations of amino acids over time was different in treated cells compared to that in the samples from untreated cells. For example, Ala concentration in the medium of untreated cells at 72 h increased by 3.0 times compared to the initial values (0 h). On the other hand, Ala concentrations in the medium of 5-FU-, CPT-11-, and CDDP-treated cells at 72 h increased 1.7, 2.6, and 2.3 times the initial concentration, respectively. Of the 21 amino acids studied, 16 (all except Asn, Cyss, Met, Ile, and Leu) in the untreated group, all of the amino acids in the 5-FU-treated group, 18 (all except Asn, Ser, and Met) in the CPT-11-treated group, and 20 (all except Met) in the CDDP-treated group were significantly altered (p < 0.05) in the sample collected following 72 h of treatment in comparison with the initial (0 h) sample. The measured concentrations of 21 amino acids in the 5-FUtreated group, 17 amino acids (all excluding Asp, Asn, Arg, and Cyss) in the CPT-11-treated group, and 19 amino acids (all excluding Gly and Met) in the CDDP-treated group were significantly altered following a 72 h of incubation with anticancer drugs (p < 0.05), in comparison to the corresponding concentrations in the untreated group. Furthermore, in the CDDP-treated groups, no significant difference in the Met concentration was observed at 72 h, compared to the same time point in the control group, despite a significant reduction in Met levels between 12 and 48 h (data not shown). 
Conclusions
We performed metabolomics analysis of amino acids using Colo201 cells treated with three anticancer drugs. Comprehensive quantification of the concentrations of 21 amino acids in the cell medium was performed by a precolumn fluorescence derivatization-HPLC method using the AccQ Tag. Differences in the relative amino acid compositions of treated cells were visualized through the PCA and PLS score plots, depicting the data as coordinates on a two-dimensional graph. The CA and DA approaches were used to classify the samples and to distinguish the effect of anticancer drug treatment on the PCA and PLS score plots. Although the CA approach could not differentiate between the three groups treated with anticancer agents and the untreated samples, the DA approach detected differences that could be visualized through boundary lines. Moreover, three amino acids (Ser, Asp and Met) were extracted from the loading plots as candidate markers, which could be used to evaluate the effect of anticancer drugs. They were different between drug-treatment groups.
These results suggested that our proposed method might be able to assess the effectiveness of these drugs. Our proposed method uses a conventional HPLC system, and could therefore be applied to assess the effectiveness of anticancer drugs in small laboratories or medical institutions.
